PRN
Profound Medical develops incision-free ablation therapies for urological conditions, focusing on transurethral ultrasound ablation for the prostate. Their TULSA-PRO system offers MRI-guided, real-time controlled ablation to treat localized prostate cancer, obstructive BPH, and other prostate diseases. The company emphasizes patient-centric, precise, and durable outcomes with regulatory clearances in major markets, and provides physician education and clinical publications to support adoption. Headquartered with operations in North America, it serves medical professionals and patients seeking minimally invasive prostate therapies.
No recent news for this company.
No recent deals for this company.